Status: Recruiting
CAR-T Therapy for Refractory Autoimmune Diseases
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases.
Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: LiangZouUpdated: Apr 22, 2026Locations: 1
Eligibility criteria
Age ≥18 years old, regardless of gender, signed with informed consent (ICF). [+15]
Previously received Chimeric Antigen Receptor T cell(CAR-T) therapy; [+9]